• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

The research on chemoprevention and therapy for oral cancer by selective inhibitors of cyclooxygenase-2

Research Project

Project/Area Number 12671957
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Surgical dentistry
Research InstitutionDepartment of Oral and Maxillofacial Surgery

Principal Investigator

YAMAMOTO Kazuhiko  Nara Medical University, Oral and Maxillofacial Surgery, Assistant Professor, 医学部, 講師 (20243842)

Co-Investigator(Kenkyū-buntansha) DENDA Ayumi  Nara Medical University, Oncological Pathology, Assistant Professor, 医学部, 講師 (90110858)
Project Period (FY) 2000 – 2001
Project Status Completed (Fiscal Year 2001)
Budget Amount *help
¥3,400,000 (Direct Cost: ¥3,400,000)
Fiscal Year 2001: ¥1,500,000 (Direct Cost: ¥1,500,000)
Fiscal Year 2000: ¥1,900,000 (Direct Cost: ¥1,900,000)
Keywordsoral cancer / cyclooxygenase-2 / 4-nitroquinoline 1-oxide / nimesulide / etodolac / chemoprevention / rat
Research Abstract

The expression of cyclooxygenase (COX)-2 is elevated in various cancer and considered to be related to carcinogen sis. We analyzed the expression of COX-2 protein in the tongue lesions induced by 4-nitroquinoline 1-oxide (4-NQO) in rats and the inhibitory efficacy of selective inhibitors, nimesulide (NIM) and etodolac. The lesions induced by 4-NQO are classified into hyperplasias, dysphasias, papillomas and squamous cell carcinomas (SCCs). The immunohistochemical expression of COX-2 protein is elevated especially in dysplasias and carcinomas. Western blot analysis showed 6-fold increase of COX-2 protein level in SCCs compared with normal epithelium. The administration of NIM and etodolac after initiation phase by 4-NQO decreased the incidences and multiplicities of SCCs dose-dependently. But, the incidences of dysphasia's, putative preneoplastic lesions, did not decreased. Then, we analyzed the effect of NIM and etodolac in the initiation phase of tongue carcinogensis by 4-NQO. The incidence of dysphasia's decreased dose-dependently. From the results described above, in rat tongue carcinogen sis, COX-2 protein level increases in dysphasia's and SCCs, and NIM and etodolac inhibit the development of dysphasia's and the progression to SCCs. Therefore, selective COX-2 inhibitors can be chemo preventive medicines for human oral cancer.

Report

(3 results)
  • 2001 Annual Research Report   Final Research Report Summary
  • 2000 Annual Research Report
  • Research Products

    (4 results)

All Other

All Publications (4 results)

  • [Publications] Hiroshi Shiotani: "Inoreasod expression of cyclooxygcnase-2 protein in 4-nitroquinoIinc 1-oxide -induccd rat tonguc osroinomas and ohernoprcventivc effiaaoy of a specific inhibitor, nianesulide"Cancer Research. 61. 1451-1456 (2001)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Hiroshi Shiotani, Ayumi Denda, Kazuhiko Yamamoto, Wakashi Kitayama, Takehiro Endoh, Yasutaka Sasaki, Masahiro Tsutsumi, Masahito Sugimura, Yoichi Konishi: "Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline 1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibito, nimesulide"Cancer Res. 61(4). 1451-1456 (2001)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Hiroshi Shiotani: "Increased expression of cyolooxygenase-2 protein in 4-nitroquinoline 1-oxide-induced rat tongue carcinomas and ohemopreventive efficacy of a specific inhibitor, nimesulide"Cancer Research. 61.4. 1451-1456 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] Hiroshi Shiotani: "Increased Expression of Cyclooxygenase-2 Protein in 4-Nitroquinoline-1-oxide-induced Rat Tongue Carcinomas and Chemopreventive Efflcacy of a Specific Inhibitor, Nimesulide"Cancer Research. 61.4. 1451-1456 (2001)

    • Related Report
      2000 Annual Research Report

URL: 

Published: 2000-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi